Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > 20 cents

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Oct 01, 2021 9:19am

70 Views

Post# 33951458

RE:20 cents

bobbybittman wrote: looks like we could go down to 20 cents

Up to this point the SP really hasn't had much reason to move since we are being held up by TSX approval of the financing deal. Once that is complete, which releases funds for phase 1 lets see what happens.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing